MedTrace Logo

A Study of a Novel Precision Medicine Approach For Obesity

NCT06814938 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2026-03-02

No results posted yet for this study

Summary

This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.

Conditions

Interventions

DRUG

Semaglutide

2.4 mg subcutaneous weekly

DRUG

Placebo

Looks exactly like the study drug, but it contains no active ingredient administered subcutaneous weekly

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Phenomix Sciences

    collaborator UNKNOWN

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Andres Acosta, MD, PhD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-21
Primary Completion
2027-12-31
Completion
2028-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06814938 on ClinicalTrials.gov